Creating a solid foundation for Genzyme's future growth, our R&D efforts include novel therapeutic candidates as well as new indications for our existing products. Explore our pipeline to see highlights of our most promising research.

Last Updated: March 5, 2015

Items marked with a * are being developed in collaboration with Alnylam and ** are being developed in collaboration with Voyager Therapeutics.

Technology
The platform or technologic approach upon which a treatment is based; either chemically synthesized like a small molecule or polymer drug, or biologic like a protein, antibody, or cell therapy.

Phase I
Clinical trials on small number of human subjects, usually healthy, primarily to assess safety and potential side effects at different dosages.

Multiple Sclerosis

We are committed to becoming a longterm partner to the MS community by working to deliver scientific advancements that will have a significant impact on the unmet needs of people living with MS.Read more

Vatelizumab
Multiple Sclerosis

mAb

Phase II

GZ402668
Multiple Sclerosis

mAb

Phase I

Edit Pipeline View

PHASES

Show All

Phase I

Phase II

Phase III

TECHNOLOGIES

In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Leber’s congenital amaurosis type 1. We have several promising programs in multiple sclerosis with molecules targeting aspects of the disease that current therapies do not adequately address, using approaches such as immunomodulation, neuroprotection, and remyelination.